Skip to content

Upstream Bio, Inc. UPB Return on assets

Return on assets at other companies

Amgen logo
AmgenAMGN
8.6%+2.1pp
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
11.3%-1.2pp
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
-35.1%-11.7pp
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
-55.6%-5.9pp
Savara logo
SavaraSVRA
-63%+4.9pp
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-20%-5.8pp

Other financials

Income statement

See full
Revenue$1.0M+82.7%
Operating income-$43.6M-36.2%
Net income-$40.6M-48.8%
EPS (diluted)-$0.75-47.1%

Balance sheet

See full
Cash & equivalents$96.7M+35.6%
Total debt$1.1M-34.5%
Total equity$304.0M-31.8%
Total assets$318.1M-30.3%

Cash flow

See full
Operating cash flow-$47.9M-16.2%
CapEx$54.0K-70.8%
Free cash flow-$30.7M-55.0%

Valuation

See full
Market cap$346.11M-40.9%
Enterprise value$250.5M-51.4%
P/S104.2×-151×

Profitability

See full
Operating margin-5,176.5%+1,764pp
Net margin-4,719%+2,752pp

Returns & leverage

See full
Return on equity-41.8%
Debt / equity0.0×
Current ratio23.1×-24.3×

Where this comes from

Calculated from Upstream Bio, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Upstream Bio, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Upstream Bio, Inc.'s return on assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Upstream Bio, Inc.'s return on assets?
Upstream Bio, Inc. (UPB) reported return on assets of -40.5% in Q1 2026.
What does return on assets mean?
Trailing-twelve-month net income divided by average total assets. Measures how efficiently the asset base generates profit, independent of how those assets are financed. Computed as net income over average total assets — note this is OpenCapital's standard definition and may differ from data vendors that use alternative numerators.